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Background. The clinical relevance of nontuberculous mycobacteria (NTM), detected by liquid more than solid culture in sputum
specimens from a South African mining workforce, is uncertain. We aimed to describe the current spectrum and relevance of
NTM in this population.Methods. An observational study including individuals with sputumNTM isolates, recruited at workforce
tuberculosis screening and routine clinics. Symptom questionnaires were administered at the time of sputum collection and clinical
records and chest radiographs reviewed retrospectively. Results. Of 232 individuals included (228 (98%)male, median age 44 years),
M. gordonae (60 individuals),M. kansasii (50), andM. avium complex (MAC: 38) were the commonest species. Of 38MAC isolates,
only 2 (5.3%) were from smear-positive sputum specimens and 30/38 grew in liquid but not solid culture. MAC was especially
prevalent among symptomatic, HIV-positive individuals. HIV prevalence was high: 57/74 (77%) among those tested. No differences
were found in probability of death or medical separation by NTM species. Conclusions.M. gordonae, M. kansasii, and MAC were
the commonest NTM amongminers with suspected tuberculosis, withmostMAC from smear-negative specimens in liquid culture
only. HIV testing and identification of key pathogenic NTM in this setting are essential to ensure optimal treatment.
1. Introduction
The nontuberculous mycobacteria (NTM) form a group of
organisms diverse in many characteristics, including path-
ogenicity and clinical disease. They have environmental res-
ervoirs and are associated with a broad spectrum of clin-
ical presentations from cutaneous to lung or disseminated
disease. There is uncertainty regarding clinical relevance of
many of the species, particularly in settings where facility to
isolate and identify them is relatively recent.
Liquid mycobacterial culture is recommended for inves-
tigation of suspected tuberculosis in resource-limited settings
[1]. Compared with solid culture, time to positive culture
is decreased and yield increased [2–4]. NTM accounted for
77% of the additional yield from liquid versus solid culture
of smear-negative sputa in a gold mining population [2]. It
is therefore important to understand the clinical relevance
of NTM isolates, particularly in settings of high HIV and
tuberculosis prevalence, where NTM may be isolated from
large numbers of individuals in tuberculosis programmes.
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Figure 1: Flow chart showing sources of study participants.
To date, there is limited information from such settings, as
culture and speciation facilities have not beenwidely available
or generally applied [5].
Gold miners in South Africa have a very high incidence
of tuberculosis [6] and high prevalence of HIV (estimated
at 29% in 2000-2001 [7]) and silicosis [8, 9]. Previous stud-
ies in this population demonstrated disease due to NTM,
particularly M. kansasii, M. scrofulaceum, and M. avium
complex [8, 10–13]. We have previously reported on NTM
species identification in this population [14] andnowdescribe
the clinical features of those withNTM isolated from sputum,
to inform laboratory and clinical practice. Previous work on
molecular characteristics of M. gordonae isolates [14] led to
the specific objective of reevaluating the clinical relevance
of M. gordonae in this setting. We used a cross-sectional,
observational study design, in the context of “Thibela TB,”
a cluster randomised trial of community-wide isoniazid
preventive therapy (IPT) [15, 16].
2. Methods
For a laboratory study evaluating mycobacterial culture
media [2], participants were recruited from two sources
(Figure 1).
BioMed Research International 3
(1) Screening for active tuberculosis at enrolment to
Thibela TB (pre-IPT screening group): enrolmentwas
open to the whole workforce. Screening was by symp-
tom questionnaire and chest radiograph; nine
months’ IPT was given to those with negative screen.
If tuberculosis was suspected at screening, sputum
was taken for mycobacterial culture. All those
providing sputum, regardless of tuberculosis history,
were eligible for this laboratory study.
(2) Clinics run by mine health services (clinic patient
group): individuals self-presented with symptoms
or were referred from occupational health services,
which conducted radiological screening of all em-
ployees every 6–12 months. Recruitment was restrict-
ed to individuals with no prior history of tuberculosis,
aiming to strengthen diagnostic services for this
group who would not routinely have been investi-
gated with sputum culture.
Participants, recruited from July 2006 to January 2009, gave
one sputum specimen, after nebulisation if necessary, and
were interviewed using a standardised symptom question-
naire, which was more detailed for the clinic patient group.
For this study, we included all those with NTM from
sputum collected up to the end of December 2007 and
with species identification using standard biochemical testing
(SBT) completed by May 2008. Those with M. tuberculosis
isolated within six months of the index NTM were excluded
as clinical disease was likely to be due to tuberculosis. The
pre-IPT screening and clinic patient groups are described
separately, as characteristics of the two groups were expected
to differ in terms of symptoms and stage of disease. Study
participants with suspected tuberculosis were referred to
the mine health service for subsequent investigation and
treatment; no additional management of patients was done
by investigators and this study was entirely observational,
reporting routine practice in this setting.
2.1. LaboratoryMethods. As described previously [2, 14], spu-
tum smears were examined for acid fast bacilli by fluores-
cencemicroscopy; 0.5mL sediment was cultured in BACTEC
MGIT 960 system (BD Diagnostic Systems, Sparks, MD,
USA) and a further 0.5mL on Lo¨wenstein-Jensen slants,
which were incubated for up to eight weeks at 37∘ Cel-
sius. Mycobacteria were identified by SBT as previously
described [14], anti-MPB64 assay (TAUNS, Numazu, Japan)
and microscopic cording. Subsequently, NTM underwent
DNA sequence amplification (using 45 amplification cycles)
and analysis of the hypervariable regions of the 16S rRNA
gene by PCR, with referral to the RIDOM and GenBank
databases for identification [17, 18]. For specimens in which
chromatograms indicated mixed NTM species, the main
species is reported; numbers with mixed species are given
in Table 1. A new species was defined as an isolate whose
sequence did not match a known sequence in the reference
databases.
2.2. Clinical Record Review. Medical and laboratory records,
accessed at primary health care centres andmining hospitals,
were reviewed retrospectively, using a standardised case
report form in order to report routine clinical practice in
this setting. Mine health services policy is to offer HIV tests
to those diagnosed with tuberculosis: tests were offered to
individuals in this study according to medical staff practice,
with no testing done for research purposes.
2.3. Chest Radiographs. The chest radiograph closest to spu-
tum specimen collection was read using a standardised
reporting form, recording features consistent with tuberculo-
sis, along with a silicosis score according to the International
Labour Office guidelines [20]. Signs were classified as consis-
tent with definite, probable, possible, or no disease for both
active and previous tuberculosis, according to the judgment
of the reader, following guidance of the chest radiograph
reading and recording system [21]. The reader was masked
to clinical details. For the pre-IPT group, an additional 10%
of radiographs were added to further mask the reader, from
those who did not have NTM isolated (no isolates or M.
tuberculosis).
2.4. Follow-Up. Individual records were linked to mine
company human resources records to establish employment
and vital status of participants. Survival analysis was used to
examine proportions remaining in the workforce by NTM
species isolated, for majority species, from the date of sputum
specimen collection. Participants were followed up from the
date of sputum specimen collection until the earliest of death,
medical separation (individuals leaving the workforce for
medical reasons), leaving employment, or censoring date (31
December 2010).
2.5. Definitions. Individuals were considered to be HIV-pos-
itive if a positive HIV test was recorded before or up to one
year following enrolment andHIV-negative if a negative HIV
test (and no subsequent positive test) was recorded after or
up to one year preceding enrolment. Treatment outcomes
for those treated with standard tuberculosis regimens were
recorded according toWHOdefinitions [22].Members of the
M. avium complex were grouped together for the most of the
descriptive work presented here.
2.6. StatisticalMethods. Categorical variables were compared
using chi-squared or Fisher’s exact test and continuous vari-
ables using the Kruskal-Wallis test. The log rank test and
Kaplan-Meier curves were used to compare proportions
remaining in the workforce by NTM species.
2.7. Ethical Approval. This study was approved by the
Research Ethics Committees of the University of KwaZulu-
Natal and the London School of Hygiene and Tropical Med-
icine. All participants gave written or witnessed verbal con-
sent.
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Table 1: Species identified using 16S sequencing, with smear status, HIV status, and CD4 counts (𝑛 = 232).
Species Number isolated(% of group)
Number (%)
smear positive
Number with mixed
species4
HIV prevalence1
(%)
Median CD42 (cells/𝜇L)
(range (number included))
Clinic patient group
M. avium complex 25 (26) 2 (8) 5 8/10 87 (14, 827 [5])
M. kansasii 21 (22) 6 (29) 3 5/8 85 (39, 763 [5])
M. parascrofulaceum 9 (9) 1 (11) 0 3/3 102 (66, 138 [2])
M. fortuitum 9 (9) 2 (22) 1 1/1 [0]
M. gordonae 7 (7) 0 1 1/1 195 [1]
New species 7 (7) 1 (14) 0 3/3 475 (236, 512 [3])
Other species 18 (19) 0 2 4/5 291.5 (154, 492 [4])
Total 96 12 (12.5) 12 (12.5% of 96 isolates) 25/31 (80.6) 215.5 (14, 827 [20])
Pre-IPT3 screening group
M. gordonae 53 (39) 8 (15) 5 10/12 298 (66, 396 [8])
M. kansasii 29 (21) 11 (38) 1 9/14 183.5 (69, 544 [8])
M. avium complex 13 (10) 0 3 4/5 211 (92, 534 [4])
M. parascrofulaceum 12 (9) 2 (17) 1 1/2 223 [1]
M. fortuitum 11 (8) 0 1 3/5 358 (245, 471 [2])
M. szulgai 5 (4) 0 2 2/2 132.5 (123, 142 [2])
New species 3 (2) 0 0 0/0 [0]
Other species 10 (7) 0 2 3/3 311 (252, 370 [2])
Total 136 21 (15.4) 15 (11.0% of 136 isolates) 32/43 (74.4) 245 (66, 544 [27])
1Fisher’s exact test for difference in HIV prevalence by species, both groups combined, 𝑃 = 0.79.
2Median CD4 count by species for those known to be HIV-positive, combining both groups (clinic patients and IPT screening group) and including 8 species
compared using Kruskal-Wallis test, which showed no evidence for difference by species, 𝑃 = 0.42.
3IPT: isoniazid preventive therapy.
4For specimens containing mixed NTM species on PCR sequencing, the main species is reported; minority species were not identified, but the numbers with
mixed species are given here. This does not apply to those with concurrentM. tuberculosis, who were excluded from this study.
3. Results
3.1. Study Population. From July 2006 to December 2007,
2496 individualswere recruited andprovided sputa. 720 spec-
imens (28.8%) yielded mycobacterial growth, as described
previously [2]. Of these, 421/720 (58.5%) grew only M.
tuberculosis and 299/720 (41.5%) grew NTM. Fifty-seven
were excluded because species identification by SBT was
not completed by May 2008; 10 were excluded because
of concurrent M. tuberculosis. Of 232 individuals included
(Figure 1), 136 were enrolled through pre-IPT screening and
96 were clinic patients.
Two hundred and twenty-eight (98.3%) of study partici-
pants were male, with median age of 44 years (interquartile
range (IQR) 36, 49 years; median age 44 years [IQR 36–
48] for pre-IPT group and 45 years [IQR 36–50] for clinic
patient group), compared with 43 years (IQR 37, 49) in the
parent laboratory study [2] and 40 (IQR 31, 46) among 23299
individuals enrolling intoThibela TB at intervention clusters
[23].Median timeworked inminingwas 21 years (IQR 10, 28).
In the pre-IPT screening group, 63/136 (46.3%) had a history
of prior tuberculosis treatment, compared with 10.7% of the
23299 enrolling at intervention clusters [23].
3.2. Mycobacterial Species and Sputum Smear Status. Species
isolated are shown in Table 1, by recruitment route. In the
clinic patient group, 25 individuals, two of whom were
sputum smear positive, had M. avium complex (12 M.
colombiense; sixM. vulneris; fiveM. intracellulare;one each of
M. avium andM. chimaera).M. kansasii was isolated from 21
individuals, six of whomwere sputum smear positive, andM.
fortuitum from nine. Seven had new mycobacterial species.
In the pre-IPT screening group,M. gordonae (53 individuals)
was the commonest species, followed by M. kansasii (29
individuals) and then members of theM. avium complex (13
participants), principallyM. colombiense (seven of 13). Eight
of 53 M. gordonae, 11 of 29 M. kansasii, and none of the M.
avium complex were isolated from smear-positive sputum
specimens.
3.3. HIV Prevalence. Combining groups, HIV status was
documented for 74/232 (31.9%) individuals (Table 1). HIV
prevalence among those with M. avium complex was 12/15
(80.0%), for M. kansasii 14/22 (63.6%), and for M. gordonae
11/13 (84.6%). Median CD4 count among HIV-positive indi-
viduals with M. avium complex was 135 cells/𝜇L (range 14,
827; 𝑛 = 9), M. kansasii 169 cells/𝜇L (range 39, 763; 𝑛 = 13),
BioMed Research International 5
Table 2: Species distribution by HIV status, among 74 individuals
with known status.
Species HIV-positive(total = 57) 𝑛 (%)
HIV-negative
(total = 17) 𝑛 (%)
M. kansasii 14 (25) 8 (47)
M. avium complex 12 (21) 3 (18)
M. colombiense 5 1
M. intracellulare 4 1
M. vulneris 3 1
M. gordonae 11 (19) 2 (12)
M. fortuitum 4 (7) 2 (12)
M. parascrofulaceum 4 (7) 1 (6)
M. szulgai 2 (4) 0
New species 3 (5) 0
Unknown 7 (12) 1 (6)
and M. gordonae 291 cells/𝜇L (range 66, 396; 𝑛 = 9). Species
distribution by HIV status is shown in Table 2.
Of 57 HIV-positive individuals, 43 (75.4%) were attend-
ing HIV care and 8/43 (18.6%) had evidence of taking
antiretroviral therapy.
3.4. Clinical andRadiological Features. Symptoms reported at
the time of sputum specimen collection are shown in Table 3.
In the clinic patient group, cough (17/25; 68.0%) and night
sweats (13/25; 52.0%) were prevalent among those with M.
avium complex. Cough was common for all NTM species
and fever was reported most frequently by those with M.
parascrofulaceum (6/9) andM. gordonae (4/7).
In the pre-IPT screening group, cough was less common
than in the clinic patient group reported by 59/136 (43.4%)
versus 66/96 (68.8%) individuals. Coughwas reported by 8/13
(61.5%) of those withM. avium complex and 26/53 (49.1%) of
those withM. gordonae.
Combining pre-IPT screening and clinic patient groups,
of 60 individuals with M. gordonae, 21 (35.0%) reported
weight loss and 14 (23.3%) night sweats, while, of 38 with
M. avium complex, 18 (47.4%) reported night sweats and 14
(36.8%) weight loss.
Chest radiographswere available for 171/232 (73.7%) indi-
viduals. Prevalence of silicosis, grade 1/0 or above, was 38/171
(22.2%) and grade 1/1 or above 13/171 (7.6%).M. kansasii was
most frequently associated with chest radiograph appearance
suggestive of definite or probable active tuberculosis (17/34,
50.0%); corresponding figures for M. avium complex were
3/26 (11.5%) and for M. gordonae 14/49 (28.6%). Lung cav-
itation was present in 47/171 (27.5%) radiographs including
22/34 (64.7%) of those with M. kansasii, 11/49 (22.5%) with
M. gordonae, 2/15 (13.3%) withM. fortuitum, and 2/26 (7.7%)
with M. avium complex (chi2 𝑃 < 0.001 for comparison of
four species). Among those with cavitation, this was con-
sidered to be due to active disease in 6/11 (54.5%) with M.
gordonae and 8/22 (36.4%) withM. kansasii.
M. gordonae isolates with discrepant identification on
SBTwere further identified by strain, as described previously,
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Figure 2: Kaplan-Meier graph showing death ormedical separation
by NTM species isolated for the three most prevalent species (𝑛 =
138: 51M. gordonae; 49M. kansasii; and 38M. avium complex).
with no differences seen between clinical features of those few
isolates identified as strainD versus otherM. gordonae strains
[14].
3.5. Species Isolated by Culture Method. Of 38 M. avium
complex isolates, 30 (78.9%) were cultured on liquid but
not solid culture medium. Of those 30, 9/12 individuals
with known status were HIV-positive and none were sputum
smear positive. For other species, 6/20 (30.0%)M. fortuitum,
38/60 (63.3%) M. gordonae, 12/50 (63.3%) M. kansasii, and
15/21 (71.4%) M. parascrofulaceum were isolated only on
liquid medium (chi2 test, 𝑃 < 0.001). Combining all spe-
cies, no significant differences in reported symptoms were
observed between those cultured on solid medium and those
cultured only on liquid medium (data not shown).
3.6. Outcomes and Loss to Workforce. Linking to human
resources data was successful for 218/232 (94.0%) individuals.
Median follow-up time was 31.9 months (range 0.07 to 54.7
months), during which time there were 10 deaths and 63
medical separations, as shown in Table 4. At 24 months,
80.3% with M. gordonae, 69.2% with M. kansasii, and 72.9%
withM. avium complex remained in the workforce (Table 5).
Comparing the three commonest species (M. gordonae; M.
kansasii; M. avium complex), log rank test for differences
in proportions remaining in the workforce gave 𝑃 = 0.47
(Figure 2).
4. Discussion
In this mining population with high HIV prevalence, NTM
were common in sputum culture of those with suspected
tuberculosis. M. gordonae, M. kansasii, and M. avium com-
plex were the commonest species, with M. avium complex
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Table 3: Symptoms reported by route of recruitment to study and species of nontuberculous mycobacterium isolated (𝑛 = 232).
Species Numberisolated
Number
reporting
cough
𝑛 (%)
Number
reporting
night
sweats1
𝑛 (%)
Number
reporting
haemoptysis
𝑛 (%)
Number
reporting
weight
loss2
𝑛 (%)
Number
reporting
fever
𝑛 (%)
Number
reporting any
symptom
𝑛 (%)
Number with chest
radiograph classified
as definite or possible
active tuberculosis
𝑛/number with chest
radiograph available
Clinic patient group
M. avium complex 25 17 (68) 13 (52) 4 (16) 11 (44) 11 (44) 19 (76) 2/14
M. kansasii 21 11 (52) 9 (43) 1 (5) 10 (48) 9 (43) 14 (67) 4/9
M. parascrofulaceum 9 8 (89) 7 (78) 0 8 (89) 6 (67) 9 (100) 1/7
M. fortuitum 9 7 (78) 5 (56) 0 5 (56) 3 (33) 7 (78) 1/5
M. gordonae 7 5 (71) 2 (29) 0 4 (57) 4 (57) 6 (86) 1/3
New species 7 5 (71) 3 (43) 1 (14) 2 (29) 4 (57) 5 (71) 0/5
Other species 18 13 (72) 11 (61) 3 (17) 7 (39) 10 (56) 15 (83) 1/7
Total 96 66 (69) 50 (52.1) 9 (9.4) 47 (49.0) 47 (49.0) 75 (78.1) 10/50
Pre-IPT3 screening group
M. gordonae 53 26 (49) 12 (23) § 17 (32) § 34 (64) 13/46
M. kansasii 29 8 (28) 2 (7.0) § 6 (21) § 12 (41) 13/25
M. avium complex 13 8 (62) 5 (39) § 3 (23) § 9 (69) 1/12
M. parascrofulaceum 12 2 (17) 2 (17) § 4 (33) § 6 (50) 4/11
M. fortuitum 11 5 (46) 3 (27) § 1 (9) § 5 (46) 5/10
M. szulgai 5 4 (80) 1 (20) § 2 (40) § 4 (80) 2/5
New species 3 1 (33) 1 (33) § 1 (33) § 1 (33) 1/2
Other species 10 5 (50) 1 (10) § 5 (50) § 6 (60) 1/10
Total 136 59 (43.4) 27 (19.9) § 39 (28.7) § 77 (56.6) 40/121
1Night sweats were defined by the wording of the question put to study participants: “Do you have drenching night sweats? (Sweat so much at night that
clothes/pillows are soaking wet?).”
2Weight loss was defined by the wording of the question put to study participants: “Do you have unintentional weight loss? (In the last 6 months have your
clothes become looser?).”
3IPT: isoniazid preventive therapy.
§Data not available as questionnaire used in pre-IPT screening for tuberculosis did not include this question.
Table 4: Deaths and medical separations, from recruitment until
end of 2010, median 32 months (𝑛 = 218).
NTM species Death
𝑛 (row %)
Medical
separation
𝑛 (row %)
Total
number of
individuals
M. gordonae 0 13 (26) 51
M. kansasii 2 (4) 16 (33) 49
M. avium complex 1 (3) 12 (32) 38
M. parascrofulaceum 2 (11) 2 (11) 19
M. fortuitum 1 (5) 11 (58) 19
M. szulgai 0 1 (20) 5
New species 1 (10) 1 (10) 10
Other species 3 (11) 7 (26) 27
Total 10 (4.6) 63 (28.9) 218
particularly prevalent among symptomatic individuals pre-
senting to routine health services and M. gordonae most
common in the pre-IPT screening group.
Table 5: Probability of remaining in the workforce during follow-up
for individuals with the three predominant NTM species.
Species 6 months(%, 95% CI)
12 months
(%, 95% CI)
24 months
(%, 95% CI)
M. gordonae 93.8 (82.0–98.0) 85.0 (91.0–92.5) 80.3 (65.5–89.3)
M. kansasii 87.3 (73.9–94.1) 78.4 (63.5–87.8) 69.2 (53.6–80.5)
M. avium
complex 88.3 (71.7–95.4) 81.7 (63.7–91.4) 72.9 (52.9–94.4)
HIV prevalence was 77.0% where known. Importantly,
though this study population comprised individuals with sus-
pected tuberculosis, a minority had HIV status documented,
suggesting that testing coverage is poor and that those tested
may not be representative of all those withNTM. It is possible
that those tested have higher prevalence of HIV than those
not tested, as theremay have been clinical reasons for offering
tests. However, routine testing in this setting is essential to
improve care and it is very likely that diagnoses of HIV are
being missed. Silicosis grade 1/1 or above (definite silicosis)
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was found in 7.6% of individuals, compared with 2.6% in the
parent study Thibela TB [16], which would be expected in a
subpopulation with NTM, as silicosis is a known risk factor
[8].
Symptoms varied by recruitment method, as expected,
with cough more prevalent among those self-presenting to
routine health services than those undergoing screening.
Lung cavitation was more prevalent among those with M.
kansasii than those with M. avium complex, which would
be expected, as M. avium complex more typically causes
disseminated disease in the context of advanced HIV-related
immunosuppression and sputum isolates may represent dis-
seminated, rather than exclusively pulmonary, disease. It is
not possible to definitively diagnose disseminated disease
without further sampling, but, with lowCD4 counts, systemic
symptoms, and chest radiographs without cavitation, it is
likely that some of this group had disseminated M. avium
complex, with the organism isolated from respiratory speci-
mens here. Similarly, radiographs were reported as consistent
with active tuberculosis less frequently in those with M.
avium complex.There was a higher than expected proportion
with cavitation on chest radiograph among thosewithM. gor-
donae. This is difficult to interpret with limited clinical data
available and cavitation may have been a result of previous or
other diseases. We did not detect differences in proportions
remaining in the workforce between groups of individuals
with the three commonest NTM species, although there is
a suggestion of lower retention in the workforce among
those with M. avium complex and M. kansasii. The study
design did not include a comparator group without NTM
and from these data alone we can only conclude that loss
to the workforce for health reasons among those with NTM
isolated from sputum is substantial. However, from the
mining population participating inThibela TB, mortality was
0.91/100 person-years and combined mortality and medical
separationwere 4.34/100 person-years [16], suggesting higher
combined mortality and medical separation among those
with NTM than the workforce overall, which may be due
to mycobacterial disease or untreated HIV. Differences by
species may have been detected with larger numbers.
The distribution of NTM species differs from that found
in previous studies in this population. In the 1990s, M.
kansasii and M. scrofulaceum were reported to be the com-
monest species [8, 11], whereas this study found higher
proportions of M. avium complex and M. gordonae, with
notable absence of M. scrofulaceum using 16S sequencing.
This is likely to be largely due to newer speciation methods:
organisms identified by SBT asM. scrofulaceum in this study
were almost all subsequently identified asM. gordonae by 16S
sequencing [14].The higher proportion ofM. avium complex
may be due to the use of liquid culture, as suggested by
laboratory studies in this population [2] and elsewhere [3, 4],
and may also be due to increased HIV prevalence in this
population: from 1.4% among thosewith sexually transmitted
infections in 1991 [24] to 19.0% among those with NTM in
1993-6 [11, 25] and 29% in a representative sample of the
workforce in 2000-1 [7]. The median age of the population
does not appear to have increased, estimated at 41 years in
2001 [7] and 40 years among those enrolling at Thibela TB
intervention clusters [23], although the median age among
those with NTM was higher.
M. gordonaewasmore prevalent in the pre-IPT screening
group than in clinic patients, perhaps because, in the con-
text of active case finding, not all isolates will be genuine
pathogens. M. gordonae is well documented to be a labo-
ratory and tap-water contaminant [19]. However, in this
group of individuals with suspected tuberculosis, M. gor-
donae was associated with systemic symptoms (night sweats,
weight loss) in some, with radiological abnormalities in 14/51
(27.5%), and with HIV infection in 11/15 (73.3%). It has
previously been reported to cause disseminated disease in
advanced HIV [26–28] and may be pathogenic in some indi-
viduals here, with isolates from sputum indicating pulmonary
or more widespread disease. Laboratory and clinical records
would be expected to have detected concurrent M. tuber-
culosis or bacterial infections if present. Longer term, close
follow-up of these individuals was not incorporated into the
study design. Without more clinical data and follow-up, firm
conclusions onM. gordonae in this population should not be
drawn, but those withM. gordonae and clinical symptoms or
abnormal radiology warrant further investigation for other
pathologies, particularly HIV infection, and repeat culture of
sputum and other relevant samples.
M. avium complex was particularly common among
symptomatic individuals in the clinic patient group, who
had high prevalence of HIV infection. M. avium complex
is known to be common where it is sought and appro-
priate diagnostics used in HIV-positive populations and
disease is associated with low CD4 cell counts [29–32].
These individuals in particular require further investigation
and specific treatment, with early antiretroviral therapy and
cotrimoxazole prophylaxis. It is noteworthy that 30/38 M.
avium complex isolates grew in liquid but not solid culture
media and none of these 30 were smear positive, suggesting
that M. avium complex infection may be underdiagnosed in
settings of highHIV prevalence where liquid culturemedium
is not used. Pulmonary isolates may reflect disseminated
disease and liquid culture will be needed to diagnose this
infection in settings where the Xpert MTB/RIF assay is
used as first line diagnostic test for tuberculosis. There
was a notable absence of M. avium, with other M. avium
complex subspecies found (M. colombiense,M. vulneris, and
M. intracellulare). This may reflect immunosuppression, as
M. colombiense is closely related to M. avium and has been
isolated fromHIV-positive individuals previously [33] ormay
reflect geographical variation in NTM species [34].
Mining populations have long been known to be at
risk of NTM infection and disease [12] and to some extent
results presented here are relevant primarily to this popu-
lation. However, comparisons of species distribution, HIV
prevalence, and clinical features are relevant to other settings
in which HIV and tuberculosis are prevalent and liquid
mycobacterial culture media are used. Similar results have
been seen in Southeast Asia in a study showing high preva-
lence of NTM isolated by liquid culture of sputum among
HIV-positive individuals, with M. kansasii most frequent in
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Table 6: AmericanThoracic Society criteria for lung disease due to NTM (adapted from [19]).
Criteria for diagnosis of lung disease due to NTM
Clinical
(1) Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan that shows
multifocal bronchiectasis with multiple small nodules
And
(2) Appropriate exclusion of other diagnoses
Microbiological
(1) Positive culture results from at least two separate expectorated sputum samples
Or
(2) Positive culture results from at least one bronchial wash or lavage
Or
(3) Transbronchial o other lung biopsy with mycobacterial histopathological features (granulomatous
inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features
and one or more sputum or bronchial washings that are culture positive for NTM
those with pulmonary disease andM. avium complex among
those with disseminated disease [35].
The clinic patient group was restricted to individuals
with no prior tuberculosis treatment, in order to maximise
the impact of the parent laboratory study on routine health
services. In addition, the clinic patient group was more
symptomatic than the pre-IPT screening group and there
are likely to have been differences in disease spectrum
between these groups. For this reason, characteristics of the
two groups are presented separately. In addition, despite
excluding individuals with M. tuberculosis isolated from
other specimens within six months of the NTM, we cannot
definitively exclude culture negative tuberculosis.
ATS criteria for lung disease due to NTM [19] include,
amongst other criteria shown in Table 6, a requirement for
NTM to be isolated from expectorated sputum samples on
more than one occasion. We were not able to apply these
criteria in this study because of its retrospective design. This
is a limitation of this study. However, authors of the ATS
criteria, primarily intended to guide diagnosis of lung disease,
are clear that they were written with the United States setting
in mind and are not validated in other settings. Among
miners in South Africa, these criteria have been shown to
be difficult to apply even in prospective studies, because of
the requirement for repeated sampling and detailed imaging
and frequent use of presumptive antimycobacterial treatment
[10] in a programme designed for tuberculosis detection and
treatment. Such repeat intensive laboratory diagnostics are
not part of the national guidelines for tuberculosis control in
South Africa [36].
5. Conclusions
In conclusion, M. avium complex, largely found among
symptomatic, smear-negative individuals, will be under-
diagnosed where liquid culture is not used. Newer culture
techniques are advisable wherever feasible, although there are
of course cost and infrastructure obstacles to widespread use.
Key pathogenic organisms should be identified where possi-
ble, so that specific treatment can be given if required. HIV
testing coverage was poor and prevalence among those with
known HIV status was high. Improved HIV testing strategies
are required for those being investigated for tuberculosis in
this and other settings of high HIV prevalence.
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